1921
Volume 101, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Japanese encephalitis virus (JEV) is the most common cause of viral encephalitis in Asia, and it is increasingly a global public health concern because of its recent geographic expansion. Although commercial vaccines are available and used in some endemic countries, JEV continues to cause illness, with more than 60,000 cases reported annually. To develop a reproducible positive control antibody useable in diagnosis of JEV infections, murine hybridomas were developed from mice inoculated with a combination of IXIARO JEV vaccine and JEV domain III of the envelope protein (E-DIII). Monoclonal antibodies (MAbs) were characterized for their ability to neutralize virus in vitro. Monoclonal antibody 17BD3-2 was found to be JEV specific and highly neutralizing, with a plaque reduction neutralization test (PRNT) endpoint titer of 1.25 μg/mL. The functional epitopes were mapped using virus neutralization escape variants to amino acid residues S309, K312, and G333 in E-DIII. This MAb may be substituted for human immune sera used as a positive control in PRNT for distribution to public health laboratories worldwide in potential future outbreaks of JEV.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0073
2019-05-20
2020-10-01
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/1/tpmd190073.html?itemId=/content/journals/10.4269/ajtmh.19-0073&mimeType=html&fmt=ahah

References

  1. Mackenzie JS, Williams DT, 2009. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health 56: 338356.
    [Google Scholar]
  2. van den Hurk AF, Ritchie SA, Mackenzie JS, 2009. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54: 1735.
    [Google Scholar]
  3. WHO, 2015. Japanese encephalitis vaccines: WHO position paper – February 2015. Wkly Epidemiol Rec 90: 6987.
    [Google Scholar]
  4. Zlatkovic J, Stiasny K, Heinz FX, 2011. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol 85: 19942003.
    [Google Scholar]
  5. Calvert AE, Huang CY, Kinney RM, Roehrig JT, 2006. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J Gen Virol 87: 339346.
    [Google Scholar]
  6. Simmons M, Nelson WM, Wu SJ, Hayes CG, 1998. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655662.
    [Google Scholar]
  7. Kohler G, Milstein C, 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495497.
    [Google Scholar]
  8. Huang CY, Silengo SJ, Whiteman MC, Kinney RM, 2005. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 79: 73007310.
    [Google Scholar]
  9. Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, Burke DS, Fournier MJ, Mason TL, 1989. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 70: 20372049.
    [Google Scholar]
  10. Kinney RM, Chang GJ, Tsuchiya KR, Sneider JM, Roehrig JT, Woodward TM, Trent DW, 1993. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5′-noncoding region and the E2 envelope glycoprotein. J Virol 67: 12691277.
    [Google Scholar]
  11. Calvert AE, Dixon KL, Delorey MJ, Blair CD, Roehrig JT, 2014. Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain. Vaccine 32: 258264.
    [Google Scholar]
  12. Fernandez E et al., 2018. Mouse and human monoclonal antibodies protect against infection by multiple genotypes of Japanese encephalitis virus. MBio 9: e00008e00018.
    [Google Scholar]
  13. Oliphant T et al., 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522530.
    [Google Scholar]
  14. Roehrig JT et al., 2013. Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. Virology 441: 114125.
    [Google Scholar]
  15. Brien JD, Austin SK, Sukupolvi-Petty S, O’Brien KM, Johnson S, Fremont DH, Diamond MS, 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84: 1063010643.
    [Google Scholar]
  16. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH, 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764769.
    [Google Scholar]
  17. Sanchez MD, Pierson TC, McAllister D, Hanna SL, Puffer BA, Valentine LE, Murtadha MM, Hoxie JA, Doms RW, 2005. Characterization of neutralizing antibodies to West Nile virus. Virology 336: 7082.
    [Google Scholar]
  18. Cecilia D, Gould EA, 1991. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181: 7077.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0073
Loading
/content/journals/10.4269/ajtmh.19-0073
Loading

Data & Media loading...

  • Received : 24 Jan 2019
  • Accepted : 04 Apr 2019
  • Published online : 20 May 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error